New blood test combined with image-based prostate cancer screening reduces harms and costs
The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study.
Materials provided by Karolinska Institutet. Note: Content may be edited for style and length.
Source link aaaaa